REQUEST A DEMO
Total
USD $0.00
Search more companies

Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. (Poland)

Main Activities: Ambulatory Health Care Services
Full name: Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. Profile Updated: May 12, 2022
Buy our report for this company USD 19.99 Most recent financial data: 2024 Available in: English & Polish Download a sample report

Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. is based in Poland, with the head office in Warsaw. It operates in the Ambulatory Health Care Services sector. Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. was incorporated on May 10, 2022. From the latest financial highlights, Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. reported a net sales revenue drop of 15.7% in 2024. There was a total growth of 54.38% in Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A.’s total assets over the same period. In, 2024, the company’s net profit margin decreased by 25.52%.

Headquarters
Ul. Zakrzewska 2/4 42
Warsaw; Mazowieckie; Postal Code: 00-737

Contact Details: Purchase the Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. report to view the information.

Website: http://www.spinamed.com.pl

Basic Information
Registered Capital:
Purchase the Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. report to view the information.
Financial Auditors:
Purchase the Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. report to view the information.
Incorporation Date:
May 10, 2022
Key Executives
Purchase this report to view the information.
Associate Partner
Company Performance
Financial values in the chart are available after Spinamed Choroby Kregoslupa Lukasz Antolak S.K.A. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
-15.7%
Total operating revenue
-15.7%
Operating profit (EBIT)
-39.8%
EBITDA
-39.8%
Net Profit (Loss) for the Period
-40.21%
Total assets
54.38%
Total equity
40.19%
Operating Profit Margin (ROS)
-27.63%
Net Profit Margin
-25.52%
Return on Equity (ROE)
-38.56%
Quick Ratio
-31.92%
Cash Ratio
-27.41%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?